What takeda pharmaceuticals (canada) does

Takeda Canada Inc. operates as the Canadian subsidiary of Takeda Pharmaceutical Company Limited, a Tokyo- and NYSE-listed global biopharmaceutical company headquartered in Toronto at Bay Adelaide Centre. The company markets and distributes prescription pharmaceutical products across six core therapeutic areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Marketed products include ENTYVIO (vedolizumab) for moderate-to-severe ulcerative colitis and Crohn's disease, and REVESTIVE (teduglutide) for Short Bowel Syndrome, the latter of which secured British Columbia Pharmacare reimbursement in May 2026. The Canadian pipeline is anchored by Zasocitinib (TAK-279), a next-generation, highly selective oral TYK2 inhibitor that demonstrated approximately 70% of patients achieving clear or almost clear skin in Phase 3 plaque psoriasis studies, positioning Takeda Canada to enter the dermatology-adjacent immunology space.

The business model is a traditional prescription pharmaceutical sales model with a one-time license revenue structure: products are prescribed by healthcare professionals and dispensed through retail, hospital, and specialty pharmacies across Canada, with reimbursement negotiated through provincial drug formularies (e.g., BC Pharmacare) and private insurance plans. Go-to-market combines a dedicated field sales organization, the Takeda Connect healthcare professional portal, the Takeda Patient Support program, and the Help At Hand patient assistance foundation. Customers are segmented as Patients and Healthcare Professionals (the two declared primary segments), with the end payer mix diversified across ten provinces plus private insurers rather than concentrated in a small number of accounts.

The company is wholly owned by Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK), which was founded in 1781 and completed the major acquisition of Shire plc in 2019 to deepen its rare diseases and specialty therapeutics franchise. In March 2026, Alan Walshe was appointed General Manager of Takeda Canada, signaling strategic continuity in pursuit of pipeline launches and provincial reimbursement expansion. Distribution and operations are scaled to support multiple reimbursable products with significant patient-services infrastructure attached.

Name

takeda pharmaceuticals (canada)

Legal name

Takeda Canada Inc.

Website

https://takedacanada.com

Company type

Public

Founded year

1781

Operating status

Operating

Short description

Takeda Canada Inc. markets and distributes prescription pharmaceuticals in gastroenterology, oncology, neuroscience, rare diseases, plasma-derived therapies, and vaccines, serving Canadian patients and healthcare professionals through pharmacy channels and provincial reimbursement programs.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD), Nutrition & Malabsorption (Celiac/Short Bowel) (HLAKAEAI), Psoriasis & Eczema Specialty Care (HLAKACAL)

Keywords

• Prescription pharmaceuticals
• Gastroenterology medicines
• Rare disease therapies
• Oncology treatments
• Patient support programs

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Prescription Pharmaceutical Sales: Takeda Canada generates revenue through the sale of prescription pharmaceutical products including innovative medicines for gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Products are sold through pharmacy and hospital channels with pricing influenced by government reimbursement and private insurance.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Takeda Canada supplies prescription pharmaceutical medicines across gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Marketed products include ENTYVIO (vedolizumab) for moderate-to-severe ulcerative colitis and Crohn's disease and REVESTIVE (teduglutide) for Short Bowel Syndrome, with pipeline candidate Zasocitinib (TAK-279), a selective oral TYK2 inhibitor for plaque psoriasis in Phase 3 development. Products are commercialized through healthcare professionals, pharmacy channels, and provincial reimbursement programs, supported by patient assistance programs and the Takeda Connect HCP portal.

Product overview

Takeda Canada operates as the Canadian subsidiary of Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. The product portfolio includes marketed therapies across gastrointestinal and inflammation (ENTYVIO for ulcerative colitis and Crohn's disease), rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Key pipeline products include Zasocitinib (TAK-279), a next-generation TYK2 inhibitor in Phase 3 for psoriasis. Patient support services include Takeda Patient Support, Help At Hand, and EntyvioConnect. Healthcare professionals access product information and services through Takeda Connect platform.

Differentiator

Problem solved

Functional benefit

Products and services

• ENTYVIO (vedolizumab) Prescription medication for moderate to severe ulcerative colitis and Crohn's disease. EntyvioConnect provides patient support including nurse education, financial assistance, and injection training kits.
• REVESTIVE (teduglutide for injection) Prescription treatment for Short Bowel Syndrome, now reimbursed in British Columbia through BC Pharmacare.
• Zasocitinib (TAK-279) Next-generation, highly selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis and other immune-mediated inflammatory diseases. Delivers rapid and durable skin clearance as a convenient once-daily pill, with Phase 3 results showing significantly greater complete skin clearance versus deucravacitinib.
• Takeda Patient Support Free patient support services including specialty pharmacy coordination, co-pay assistance, and nursing support for patients prescribed Takeda therapies.
• Help At Hand Patient assistance program providing Takeda medicines to eligible patients who have no insurance or insufficient insurance coverage.
• Takeda Connect Healthcare professional portal providing access to product information, practice support, personalized services, and educational content for prescribers of Takeda medicines.
• Global Patient Access Request Form Healthcare professional portal for submitting patient access requests for Takeda treatments.

Quantifiable outcome

• Approximately 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies with zasocitinib

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• UCB: UCB is a focused immunology player with established Crohn's disease and psoriasis assets (e.g., Cimzia), directly competing with Takeda in IBD and dermatology specialty biologics.
• AbbVie: AbbVie competes directly with Takeda in IBD (Skyrizi, Rinvoq) and plaque psoriasis (Skyrizi), targeting the same gastroenterology and dermatology specialties with both biologics and oral therapies.
• Johnson & Johnson: J&J's Janssen division directly competes with Takeda in IBD through Stelara and Tremfya and is one of the largest established players in immunology and gastroenterology globally.
• Bristol Myers Squibb: BMS markets Zeposia for ulcerative colitis and Crohn's disease, directly overlapping Takeda's ENTYVIO franchise in gastroenterology, and is a meaningful competitor in immunology.
• Eli Lilly: Lilly's Taltz competes with Takeda in plaque psoriasis and the company is advancing IBD assets, making it a direct immunology peer with overlapping dermatology and gastroenterology coverage.

Broad incumbents

• Sanofi: Sanofi is a broader biopharmaceutical incumbent whose Dupixent franchise competes with Takeda in dermatology and inflammatory disease, overlapping with Takeda's immunology focus areas.
• Pfizer: Pfizer is a global pharmaceutical incumbent with overlap in oncology, vaccines, and gastroenterology, and competes broadly with Takeda's diversified specialty portfolio.
• Novartis: Novartis is a major global biopharma with overlapping therapeutics in gastroenterology, neuroscience, and oncology, providing an incumbent counterpoint to Takeda's specialty portfolio strategy.
• Roche: Roche is a leading biopharmaceutical company with biologics franchises that overlap with Takeda in oncology and immunology, including IBD-adjacent biologic portfolios.
• Amgen: Amgen is a biologics-focused biopharma competing in inflammation and biosimilars; its portfolio overlaps with Takeda in inflammation/IBD and as a future ENTYVIO biosimilar threat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/takeda-pharmaceuticals
• LinkedInlinkedin.com/company/takeda-canada-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about takeda pharmaceuticals (canada)